Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01456351

Recruitment Status : Completed

First Posted : October 20, 2011

Last Update Posted : February 12, 2013

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Jurgen Barth, University of Giessen

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	August 2010
Actual Study Completion Date :	December 2010

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Erratum In: Lancet Oncol. 2016 Jan;17(1):e6.

To Top